Attenuation of bleomycin-induced lung fibrosis by oral sulfhydryl containing antioxidants in rats

Basit Öğe Kaydı
dc.authoridArmutcu, Ferah/0000-0002-3218-9480
dc.authorwosidulu, ramazan/V-9751-2018
dc.authorwosidArmutcu, Ferah/A-1364-2019
dc.contributor.authorYidirim, Z
dc.contributor.authorKotuk, M
dc.contributor.authorIraz, M
dc.contributor.authorKuku, I
dc.contributor.authorUlu, R
dc.contributor.authorArmutcu, F
dc.contributor.authorOzen, S
dc.date.accessioned2024-08-04T20:14:46Z
dc.date.available2024-08-04T20:14:46Z
dc.date.issued2005
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAntioxidant therapy may be useful in diseases with impaired oxidant antioxidant balance such as lung fibrosis. The effects of sulfhydryl-containing antioxidant agents N-acetylcysteine (NAC) and erdosteine on the bleomycin-induced lung fibrosis were compared in rats. The animals were divided into four groups: Vehicle + vehicle, vehicle + bleomycin (2.5 U/kg), bleomycin + erdosteine (10 mg/kg), and bleomycin + NAC (3 mmol/kg). Bleomycin administration resulted in prominent lung fibrosis as measured by lung hydroxylproline content and lung histology which is almost completely prevented by erdosteine and NAC. Hydroxyproline content was 18.7 +/- 3.5 and 11.2 +/- 0.6 mg/g dried tissue in bleomycin and saline treated rats, respectively (P < 0.001), and this level was 11.3 +/- 1.2 and 13.8 +/- 1.2 mg/g dried tissue in erdosteine and NAC pretreated, respectively. Erdosteine and NAC significantly reduced depletion of glutathione peroxidase, and prevented increases in myeloperoxidase activities, nitric oxide, and malondialdehyde levels in lung tissue produced by bleomycin. Data presented here indicate that erdosteine and NAC similarly prevented bleomycin-induced lung fibrosis and their antioxidant effects were also similar in this experiment. (c) 2005 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.pupt.2005.02.001
dc.identifier.endpage373en_US
dc.identifier.issn1094-5539
dc.identifier.issue5en_US
dc.identifier.pmid15939316en_US
dc.identifier.scopus2-s2.0-20444377322en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage367en_US
dc.identifier.urihttps://doi.org/10.1016/j.pupt.2005.02.001
dc.identifier.urihttps://hdl.handle.net/11616/93965
dc.identifier.volume18en_US
dc.identifier.wosWOS:000230191700008en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAcademic Press Ltd Elsevier Science Ltden_US
dc.relation.ispartofPulmonary Pharmacology & Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbleomycinen_US
dc.subjectlung fibrosisen_US
dc.subjectN-acetylcysteineen_US
dc.subjecterdosteineen_US
dc.subjectratsen_US
dc.titleAttenuation of bleomycin-induced lung fibrosis by oral sulfhydryl containing antioxidants in ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu